Accura BioTech Secures Over RMB 100 Million Series A Funding to Advance Coagulation Diagnostics

VCBeat has learned that Shandong Aikeda Biotechnology Co., Ltd. (hereinafter referred to as “ACCURDX”) recently announced the completion of its Series A financing round, exceeding RMB 100 million.This round of financing was jointly invested by ADDOR and CITIC Medical Fund, with Ruiling Capital serving as the exclusive financial advisor for this round.The funds from this round of financing will support ACCURDX in deepening its expertise in the coagulation field and the R&D and production of reagent raw materials, expanding production capacity, accelerating the commercialization of R&D achievements, and building a team of high-caliber talent.

ACCURDX, established in 2017, is an innovative enterprise specializing in hemostasis and thrombosis testing technologies. It integrates the research and development, manufacturing, sales, and technical services of raw materials, diagnostic reagents, diagnostic instruments, and automated laboratory automation lines.The product portfolio encompasses coagulation testing systems, immunoassay systems, specific protein testing systems, and reproductive health testing systems, providing automated clinical laboratory solutions for hemostasis and thrombosis, cardiovascular and cerebrovascular diseases, and colorectal cancer screening.

ACCURDX is committed to independent research and development, dedicated to providing sophisticated products and precise automation solutions for clinical diagnostics. The company has established eight R&D centers in Jinan, Beijing, Shanghai, Suzhou, and other locations, building a comprehensive R&D system that covers the entire industry chain, including raw materials, reagents, analytical instruments, operating software, and automation.

Since its establishment, ACCURDX has obtained 45 production licenses, registration certificates for 10 fully automated analyzers, and registration certificates for 35 reagent kits, along with 83 patents including invention patents. The company has successively received numerous honors and accreditations, such as National “High-Tech Enterprise,” Shandong Province “Specialized, Refined, Differential, and Innovative” Enterprise, Shandong Provincial Engineering Research Center for Biomarker Detection Technology, Shandong Provincial Key Laboratory of Medical Physics and Image Processing Technology, Jinan Municipal Key Laboratory for Innovation in In Vitro Diagnostics of Cardiovascular Diseases, and Jinan Municipal “One Enterprise, One Technology” R&D Center.

Wang Xing, the company's founder and chairman, stated: We sincerely thank our investors for their trust and support in ACCURDX, which is a strong endorsement of the company’s management team, innovative development strategy, and execution capabilities.

ACCURDX’s core product strategy focuses on comprehensive clinical laboratory solutions for hemostasis and thrombotic disorders, alongside the increasingly refined R&D of diagnostic biomarkers for cardiovascular and cerebrovascular diseases. The company will continue to prioritize technological innovation and independent R&D, accelerating the development of new fully automated coagulation analysis systems and open intelligent testing platforms. This effort aims to lay a solid foundation for enhancing the manufacturing standards of domestically produced medical devices. Furthermore, in building innovative technology platforms, ACCURDX seeks to promote industry-academia-research collaboration and cultivate a new generation of key technical talent. We hope to work together with our investment partners to drive the overall development of the industry and make unremitting efforts to fulfill our mission of “Precision Diagnosis, Serving Health.”

Zhao Jie, Investment Director at ADDOR, statedCoagulation and hemostasis testing holds significant clinical value, and this market is currently still dominated by foreign diagnostic companies. We are optimistic about the long-term development of the coagulation field and believe that domestic companies with technological and cost advantages will stand out amidst industry transformation and progress. ACCURDX has assembled a team led by industry experts, boasting solid technical strength and extensive industry experience. It has demonstrated exceptional R&D capabilities and a craftsman’s dedication to refining high-quality products. We look forward to partnering with ACCURDX to make greater contributions to the development of the in vitro diagnostics industry.

Zhang Yan, Investment Director of CITIC Medical Fund, statedDeveloping IVD diagnostic raw materials with independent intellectual property rights and performance comparable to world-leading standards has become the main theme for the long-term, stable development of China’s IVD sector. ACCURDX has established a raw material R&D center in Suzhou, achieving independent research and development and ensuring an autonomous and controllable supply chain, thereby addressing the critical bottleneck issue of high-quality antibodies. The company has also achieved innovative breakthroughs in high-throughput instruments by designing multiple modules, realizing a comprehensive industrial layout encompassing reagents, instruments, and automation lines. By continuously driving technological advancements in its products, we are highly optimistic about the company’s future development, looking forward to further achieving domestic superiority in the IVD field and accelerating the process of import substitution.

ADDOR was established through the mixed-ownership reform of Jiangsu High-Tech Investment Group, a well-established and renowned venture capital firm. It ranks among the industry leaders in terms of industry research capabilities, assets under management, and investment specialization, making it one of the most influential venture capital institutions in China. As of the end of June 2022, ADDOR’s management team had cumulatively managed RMB 121.8 billion in capital, invested in and supported over 1,135 startups, and helped 223 of these companies list on domestic and international capital markets.

CITIC Medical Fund is CITIC’s equity investment management platform dedicated to the healthcare sector, committed to building a comprehensive, empowerment-oriented pharmaceutical industry fund with deep industry integration capabilities. The fund’s team comprises industry specialists with extensive senior operational experience at multinational pharmaceutical companies and financial experts with deep expertise in the finance sector.

RuiLing Capital is committed to becoming a leading primary market underwriter in China, recommending outstanding enterprises and exceptional entrepreneurs to professional investors both domestically and internationally. Currently, the firm focuses on the healthcare and wellness sector, paying close attention to the growth of companies in specialized medical fields. It helps enterprises gain capital empowerment and provides financial advisory, private equity, and mergers and acquisitions services to early- and mid-stage companies. Professionalism is the hallmark of RuiLing’s team, which brings together professionals with expertise in investment banking, medicine, biotechnology, and other fields, all focused on innovative, high-growth opportunities. Since its establishment in 2018, the company has served clients across multiple healthcare sub-sectors, including innovative medical devices, in vitro diagnostics (IVD), precision medicine, healthcare services, and biotechnology.